NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
SOUTH SAN FRANCISCO, Calif., March. 22, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
- Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway into the second half of 2023 - Four antibody-drug conjugate programs are now in the clinic that were discovered through Sutro’s proprietary and integrated...
Sutro Biopharma Presents at the 11th Annual World ADC Europe 2021 – PowerPoint Presentation
Download the presentation, CLICK HERE
Bill Newell, CEO Interviewed by Biotech 2050
Episode 47. Next Generation Cell Free Cancer and Autoimmune Therapeutics, Bill Newell, CEO, Sutro Biopharma
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
39th Annual JP Morgan Healthcare Conference – Presentation
Webcast, CLICK HERE Download Presentation, CLICK HERE
BioSpace – Sutro Biopharma Maximizes Synergy to Treat Cancer and Preserve Quality of Life
https://www.biospace.com/article/sutro-maximizes-synergy-to-treat-cancer-and-preserve-quality-of-life/ By: Heather McKenzie Published: Jan. 12, 2021 Sutro Biopharma wants to use its antibody-drug conjugates (ADCs) as “laser-guided weapons” against cancer cells...
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
South San Francisco, Calif., Dec. 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
